• Explore /
  • Poster
  • / Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

Abstract Poster

Authors

null

Hun Ju Lee

The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX

Hun Ju Lee , Michael Y. Choi , Tanya Siddiqi , Joanna Meehan Rhodes , William G. Wierda , Iris Isufi , Joseph M. Tuscano , Nicole Lamanna , Suki Subbiah , Jean Louise Koff , Lori Ann Leslie , Alec Goldenberg , Gina G. Chung , Salim Yazji , Yao Wang , James Bradley Breitmeyer , Michael Wang , Catriona Jamieson , Thomas J. Kipps

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT03088878

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7520)

DOI

10.1200/JCO.2022.40.16_suppl.7520

Abstract #

7520

Poster Bd #

174

Abstract Disclosures

Similar Posters

First Author: Hun Ju Lee

First Author: Hun Ju Lee

Poster

2019 ASCO Annual Meeting

Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.

Phase 1/2 trial of cirmtuzumab and ibrutinib: Planned analysis of phase 1 CLL cohorts.

First Author: Michael Y. Choi

First Author: Pier Luigi Zinzani